Shares of biopharmaceutical company Synlogic (NASDAQ:SYBX) are on the rise today after its product candidate SYNB1934 bagged an orphan drug designation from the U.S. Food and Drug Administration for the treatment of phenylketonuria (PKU).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Next, Synlogic is planning to begin a Phase 3 trial of the drug in the first half of 2023. Impressively, SYNB1934 has also bagged a Rare Pediatric Disease designation in the U.S. as well as an orphan drug designation in Europe.
Today’s price gains come after a nearly 55.5% drop in Synlogic shares over the past year.
Read full Disclosure